12 Health Care Stocks Moving In Wednesday's Intraday Session

Benzinga · 04/16 17:06
Gainers
- icad (NASDAQ:ICAD) stock moved upwards by 73.0% to $3.34 during Wednesday's regular session. The market value of their outstanding shares is at $88.0 million.
- Universe Pharmaceuticals (NASDAQ:UPC) stock increased by 26.25% to $4.18. The market value of their outstanding shares is at $63.6 million.
- Zhengye Biotechnology (NASDAQ:ZYBT) stock increased by 22.87% to $7.09. The company's market cap stands at $336.0 million.
- Mira Pharmaceuticals (NASDAQ:MIRA) shares rose 21.48% to $1.09. The company's market cap stands at $18.0 million.
- Jupiter Neurosciences (NASDAQ:JUNS) shares rose 18.94% to $0.69. The company's market cap stands at $22.8 million.
- Phio Pharma (NASDAQ:PHIO) shares moved upwards by 18.11% to $2.87. The company's market cap stands at $13.7 million.
Losers
- Syra Health (NASDAQ:SYRA) stock declined by 34.4% to $0.13 during Wednesday's regular session. The market value of their outstanding shares is at $1.6 million.
- Biomerica (NASDAQ:BMRA) stock fell 26.31% to $0.42. The market value of their outstanding shares is at $7.7 million. The company's, Q3 earnings came out 2 days ago.
- China SXT Pharmaceuticals (NASDAQ:SXTC) stock decreased by 19.52% to $1.37. The company's market cap stands at $18.8 million.
- MSP Recovery (NASDAQ:MSPR) shares declined by 19.05% to $1.87. The market value of their outstanding shares is at $3.9 million. As per the news, the Q4 earnings report came out today.
- Acrivon Therapeutics (NASDAQ:ACRV) shares declined by 17.24% to $1.78. The company's market cap stands at $55.4 million.
- LogicMark (NASDAQ:LGMK) shares fell 15.84% to $0.01. See Also: www.benzinga.com/money/best-healthcare-stocks/
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.